Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

35 results about "Tenofovir" patented technology

Tenofovir is used with other HIV medications to help control HIV infection.

Tenofovir Spray Drying Sachet Enema Powder Formulation for HIV Prevention

PendingUS20250325482A1Organic active ingredientsPowder deliveryPre-exposure prophylaxisSpray dried
Provided herein are stable formulations containing active ingredients, such as antiviral compositions, or antiretroviral compositions in a powder form for reconstitution for intrarectal delivery to provide pre-exposure prophylaxis (PrEP) against viral infections. The antiviral composition may be tenofovir, for HIV PrEP.
Owner:JOHNS HOPKINS UNIVERSITY +2

Compositions and methods for treating hepatitis b virus infection

Hepatitis B is severe liver infection caused by hepatitis B virus (HBV). At present, methods for treating HBV infection have serious limitations. An antiviral drug, such as tenofovir, as a nucleotide reverse transcriptase inhibitor, can reduce viral replication but cannot cure HBV infected patients. Due to the liver injury degree caused by HBV, transplantation needs to be carried out under some conditions. In addition to the inherent risk of organ transplantation, the cost of the organ transplantation may be scared. Therefore, an improved method for treating HBV infection is urgently required. The present invention features compositions and methods for introducing mutations into the genome of Hepatitis B Virus (HBV).
Owner:BEAM THERAPEUTICS INC +4

Pharmaceutical compositions comprising antiviral agents and optionally steviol glycosides

PCT designated stage expiredWO2025029760A1Organic active ingredientsAntiviralsAlkaneGlycoside
The disclosure in one aspect provides a pharmaceutical composition of an antiviral agent, the pharmaceutical composition comprising: the antiviral agent, which can be tenofovir; and a PEG-saccharide-lipid conjugate having the structural formula wherein m has a number-average value in the range of 2-10; S is a mono-, di- or trisaccharide group; L is -C(O)-R1 in which R1 is an alkanyl or alkenyl group having a number- average number of carbons in the range of 6-22, and / or is a steroid acyl group; P is -(CH2-CH2-O)nR2 in which n has a number-average value in the range of 5-50 and R2 is hydrogen and / or alkanyl and has a number average number of carbons in the range 0-4. Such compositions can be provided in a variety of forms. In various such embodiments, the pharmaceutical composition further includes one or more steviol glycosides mainly comprising one or more steviosides and / or rebaudiosides.
Owner:UKRAINIAN INDEPENDENT INFORMATION AGENCY

Application of a TDF in the regulation of serum cholesterol and a verification method

The application relates to the field of biological medicine, in particular to application of TDF in serum cholesterol regulation and a verification method. The application discloses that tenofovir disoproxil fumarate (TDF) can inhibit intestinal cholesterol absorption by specifically down-regulating the expression level of NPC1L1 protein in the intestinal tract, so as to reduce serum cholesterol. The regulation has tissue specificity, and TDF has no significant influence on the expression of key genes of liver cholesterol metabolism. The application also provides a method for verifying the regulation of TDF on serum cholesterol, which is evaluated by detecting blood lipid indexes and the gene and / or protein expression level of NPC1L1 in duodenal tissue. The application provides a treatment scheme with antiviral and cholesterol-lowering effects for patients with chronic hepatitis B combined with hypercholesterolemia, and provides a new idea for developing a lipid-lowering strategy targeting intestinal cholesterol absorption.
Owner:THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIV

Method for detecting related substances in emtricitabine-propofol-tenofovir disoproxil fumarate tablets

PendingCN121899285AComponent separationEmtricitabineGradient elution
The invention relates to the technical field of drug analysis and detection, and particularly discloses a method for detecting related substances in emtricitabine, propiophenol and tenofovir disoproxil fumarate tablets. According to the method, an octadecyl silane bonded silica gel chromatographic column is adopted, a mixed solution of a phosphate buffer solution and a tetrahydrofuran-acetonitrile solution in different volume ratios is taken as a mobile phase A and a mobile phase B respectively, and a gradient elution mode is adopted by a dual-wavelength high-performance liquid chromatography; the method can realize effective separation of a plurality of impurities in the emtricitabine, propofol and tenofovir disoproxil fumarate tablet, and accurately detect the condition of the impurities in the emtricitabine, propofol and tenofovir disoproxil fumarate tablet. The methodology research and verification of specificity, sensitivity and the like of the method provided by the invention find that the method provided by the invention is sensitive, accurate and relatively good in reproducibility, and accurate and quantitative detection of the related substances in the emtricitabine, propofol and tenofovir disoproxil tablet can be realized by using a simple, convenient and rapid method; and a reliable guarantee is provided for improving and better controlling the quality of the emtricitabine, propofol and tenofovir disoproxil fumarate tablet product.
Owner:NORTH CHINA PHARMA HUAKUN HEBEI BIOTECH

Dolutegravir, tenofovir and lamivudine compound tablet

The present invention relates to a dolutegravir-tenofovir-lamivudine combination tablet. Specifically, the present invention provides a dolutegravir-tenofovir-lamivudine combination bilayer tablet, comprising a first immediate-release tablet and a second immediate-release tablet; the first immediate-release tablet comprising dolutegravir, lamivudine, a diluent, optionally a binder, and optionally a disintegrant; and the second immediate-release tablet comprising tenofovir disoproxil, a diluent, optionally a binder, and optionally a disintegrant. The dolutegravir-tenofovir-lamivudine combination tablet of the present invention has a fast dissolution rate and high stability, thereby having excellent bioequivalence and shelf life.
Owner:SHANGHAI DESANO BIO PHARM CO LTD

Vaginal nanofiber formulations containing tenofovir disoproxyl fumarate and emtricitabine.

ActiveTR202519189A3Organic active ingredientsAntiviralsEmtricitabineDrug release
This relates to electrospinning-produced, layered vaginal nanofiber formulations for local prophylaxis against vaginal transmission of HIV / AIDS. The formulation contains Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC). Thanks to its mucoadhesive properties, it adheres firmly to the vaginal mucosa, providing long-lasting local drug release. Its layered structure and controlled release profile increase its effectiveness and reduce systemic side effects.
Owner:GAZI UNIVERISTESI

Pharmaceutical Formulations Comprising Tenofovir Alafenamide And Emtricitabine

ActiveUS20260151343A1Organic active ingredientsAntiviralsEmtricitabineTenofovir alafenamide
The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.
Owner:GILEAD SCIENCES INC

Pharmaceutical composition and method of treating hepatitis

A pharmaceutical composition including an active ingredient, wherein the active ingredient includes at least a first drug conjugate having a structure shown by the following formula: Z-(linker-[R]m)n. In the formula, Z is a drug compound, R is a sugar, and m and n are independently an integer from 1 to 6. The drug compound Z is a first drug compound X selected from the group consisting of Tenofovir, Tenofovir diisoproxil, Tenofovir alafenamide, Entecavir, Telbivudine, Adefovir, Adefovir dipivoxil, Lamivudine, Interferon-α-2A, Interferon-α-2B, Selgantolimod, BI-82 and Zosuquidar, and the sugar R is selected from the group consisting of a monosaccharide, a disaccharide, a trisaccharide, a tetrasaccharide, an oligosaccharide, and a polysaccharide.
Owner:SEECURE TAIWAN CO LTD

Application of nucleoside reverse transcriptase inhibitor in preparation of medicine for preventing and treating premature delivery

The invention provides application of a nucleoside reverse transcriptase inhibitor tenofovir in preparation of a medicine for preventing and treating premature delivery. Experiments find that LINE1 activation and retrotransposon induced by S100A9 nuclear translocation during delivery initiation can be used as new targets for preventing and treating premature delivery, and a nucleoside reverse transcription inhibitor tenofovir can prevent and treat premature delivery by blocking LINE1 activation and retrotransposon as well as type I interferon reaction and cell senescence of fetal membrane cells induced by LINE1 activation and retrotransposon.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Separation and detection method of tenofovir and enantiomer

The invention provides a tenofovir and enantiomer separation and detection method, and belongs to the field of pharmaceutical analysis. Octadecylsilane chemically bonded silica is adopted as a filler chromatographic column, a mobile phase is a mixed solution of a mixed aqueous solution (D-phenylalanine, copper sulfate pentahydrate and ammonium dihydrogen phosphate) and methanol, and tenofovir and enantiomers can be effectively separated and accurately determined. The method disclosed by the invention is simple, convenient, high in sensitivity, good in separation degree and reproducibility and accurate and reliable in result, and can be used for detecting tenofovir diastereoisomers and enantiomers.
Owner:SUZHOU LANXITE BIOTECH

Pharmaceutical formulations comprising tenofovir and emtricitabine

PendingCN119606990AOrganic active ingredientsAntiviralsEmtricitabineTenofovir alafenamide
The present invention provides a solid oral dosage form comprising tenofovir alafenamide, or a pharmaceutically acceptable salt thereof, and emtricitabine, or a pharmaceutically acceptable salt thereof.
Owner:GILEAD SCIENCES INC

Tenofovir spray drying sachet enema powder formulation for HIV prevention

Provided herein are stable formulations containing active ingredients, such as antiviral compositions, or antiretroviral compositions in a powder form for reconstitution for intrarectal delivery to provide pre-exposure prophylaxis (PrEP) against viral infections. The antiviral composition may be tenofovir, for HIV PrEP.
Owner:UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION +2

Application of tenofovir disoproxil fumarate

The invention discloses an application of tenofovir disoproxil fumarate in preparation of a medicine for preventing or / and treating alpha-synucleinopathy, and also discloses a related combined application of the tenofovir disoproxil fumarate. Specifically, the tenofovir disoproxil fumarate protects neurons by reducing the level of alpha-synuclein in nerve cells and relieving behavior defects induced by alpha-synuclein, realizes effective prevention and treatment of alpha-synucleinopathy, and improves the insufficiency of the efficacy of existing drugs.
Owner:THE FOURTH AFFILIATED HOSPITAL OF ZHEJIANG UNIV SCHOOL OF MEDICINE

Packaging box (emtricitabine and tenofovir disoproxil fumarate tablets)

ActiveCN310084597SEmtricitabineMetformin Hydrochloride
1. Name of the design product: packaging box (metformin hydrochloride and pioglitazone hydrochloride tablet). 2. Use of the design product: the design product is used for the packaging of medicines. 3. Design points of the design product: the combination of shape and pattern. 4. Picture or photo best indicating the design points: perspective view.
Owner:LUNAN PHARMA GROUP CORPORATION

High performance liquid chromatography detection method for inomitib related substances

The invention provides a high performance liquid chromatography detection method of an inomitib tablet related substance. Specifically, the invention provides a method for detecting the related substances of the inomitetib tablets, which comprises a detection method for separating and detecting a related substance A from tenofovir disoproxil fumarate-inovirine and a detection method for separating and detecting a related substance B from lamivudine. The detection method disclosed by the invention can be used for rapidly and effectively separating and detecting all the related substances in the inomitib tablets, and an effective method is provided for controlling the related substances in the inomitib tablets.
Owner:成都艾迪医药技术有限公司 +1

Post-treatment method for tenofovir production

PendingCN119708059AGroup 5/15 element organic compoundsDiethyl methylphosphonateStrong acids
The invention relates to the technical field of medicine synthesis, in particular to a synthesis post-treatment method of tenofovir. The preparation method comprises the following steps: carrying out nucleophilic substitution reaction on (R)-9-(2-hydroxy propyl) adenine and p-toluenesulfonyloxy diethyl methylphosphonate under the condition that magnesium tert-butoxide is used as alkali, hydrolyzing under the action of strong acid to obtain tenofovir, and concentrating to remove acid; washing off other impurities after passing through an activated cation exchange resin column; then, the tenofovir is eluted with alkali; and adjusting the pH value to separate out a product, thereby obtaining qualified tenofovir. According to the technical scheme, the synthesis post-treatment method of tenofovir is less in three industrial wastes, the resin column can be repeatedly used, meanwhile, the product yield can be improved, and industrial production of tenofovir is facilitated.
Owner:LONZEAL PHARMA

Combination of sirna agent and reverse transcriptase inhibitor and use thereof in treating hepatitis b

The present application provides a combination of an siRNA agent and a reverse transcriptase inhibitor and a use thereof in treating hepatitis B. The present application specifically relates to a drug combination of an siRNA agent and tenofovir or a pharmaceutically acceptable prodrug thereof or a pharmaceutically acceptable salt thereof, a drug combination of an siRNA agent and entecavir or a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutical use thereof.
Owner:CHIA TAI TIANQING PHARMA GRP CO LTD

Vaginal nanofiber formulations containing tenofovir disoproxyl fumarate and emtricitabine.

This relates to electrospinning-produced, layered vaginal nanofiber formulations for local prophylaxis against vaginal transmission of HIV / AIDS. The formulation contains Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC). Thanks to its mucoadhesive properties, it adheres firmly to the vaginal mucosa, providing long-lasting local drug release. Its layered structure and controlled release profile increase its effectiveness and reduce systemic side effects.
Owner:GAZI UNIVERISTESI

Tenofovir alafenamide compositions

The present invention provides oral pharmaceutical compositions of tenofovir alafenamide succinate, polymorph, cocrystal thereof, alone or in combination with one or more anti-viral drug and one or more pharmaceutically acceptable excipients. The present invention provides oral pharmaceutical compositions of tenofovir alafenamide succinate in combination with one or more anti-viral drug and one or more pharmaceutically acceptable excipients.
Owner:LUPIN LTD

Preparation method of tenofovir prodrug

The present invention relates to a method for preparing 9-[(R)-2-[[(S)-[[[1-(isopropoxycarbonyl)-1-methyl]ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine fumarate of a compound of formula (I). The method comprises taking (R)-9-(2-methoxypropyl phosphate)-adenine as a starting material, first reacting it with phenol in the presence of a condensing agent to obtain compound (II); further chlorinating compound (II) to obtain compound (III-1), which is then condensed with compound (IV) to obtain compound (V); salifying compound (V) with D-(+)-dibenzoyltartaric acid anhydrate, followed by separation in an acetone / water mixed solvent to obtain compound (VI); dissociating compound (VI) through crystallization to obtain compound (VII); and finally salifying compound (VII) with fumaric acid to obtain a finished compound of formula (I). This synthetic method has high yield, good stability, simple operation, and is suitable for industrial production of pharmaceuticals. #imgabs0#
Owner:JIANGSU HANSOH PHARMA CO LTD +1

Preparation method of novel tenofovir prodrug

The invention relates to a preparation method of a compound 9-[(R)-2-[[(S)-[[[1-(isopropoxycarbonyl)-1-methyl] ethyl] amino] phenoxyphosphinyl] methoxyl] propyl] adenine fumarate as shown in a formula (I), which comprises the following steps: taking (R)-9-(2-phosphate methoxyl propyl)-adenine as a starting material, and firstly reacting with phenol under a condensing agent to obtain a compound (II); further chlorinating the compound (II) to obtain a compound (III-1), condensing the compound (III-1) with a compound (IV) to obtain a compound (V), salifying the compound (V) with D-(+)-dibenzoyl tartaric acid anhydride, splitting in an acetone / water mixed solvent to obtain a compound (VI), and performing free crystallization on the compound (VI) to obtain a compound (VII), and finally, salifying the compound (VII) and fumaric acid to obtain a compound finished product shown in the formula (I). The synthesis method is high in yield, good in stability, simple to operate and suitable for industrial production of medicines. # imgabs0 #
Owner:JIANGSU HANSOH PHARMA CO LTD +1

Preparation method of tenofovir intermediate R-(+)-9-(2-hydroxypropyl) adenine

PendingCN120483983AOrganic chemistryTetramethylammonium bromideCombinatorial chemistry
The invention belongs to the technical field of chemical pharmacy, and relates to a preparation method of a tenofovir intermediate R-(+)-9-(2-hydroxypropyl) adenine, adenine and R-propylene oxide are used as raw materials, tetraethylammonium bromide is used as a catalyst, under the action of sodium hydroxide, a ring-opening condensation reaction is carried out, and the tenofovir intermediate R-(+)-9-(2-hydroxypropyl) adenine is obtained. And the tenofovir intermediate R-(+)-9-(2-hydroxypropyl) adenine is generated. According to the preparation method of the tenofovir intermediate R-(+)-9-(2-hydroxypropyl) adenine, provided by the invention, the content of isomer impurities is greatly reduced, and the yield of a finished product is improved.
Owner:LEPING SAFELY PHARMA

Method for synthesizing and preparing tenofovir

The invention relates to a tenofovir synthesis and preparation method, and belongs to the technical field of pharmacy. Comprising the following steps: 1) adding (R)-9-(2-hydroxypropyl) adenine into an organic solvent solution with a catalyst, adding p-toluenesulfonyloxymethyl diethyl phosphate at the same time, and carrying out heating reaction to generate tenofovir diethyl ester; (2) adding strong acid into the tenofovir diethyl ester, heating and hydrolyzing to obtain a tenofovir product; and 3) after hydrolysis is completed, cooling a reaction system, filtering to remove salt, concentrating hydrochloric acid, and adjusting alkali to obtain tenofovir. The production cost can be reduced from the two aspects of production raw materials and the production process, the method has the advantages that the production efficiency is improved, the production period is shortened, the production cost is reduced and the like, and better commercial production of tenofovir can be realized.
Owner:LONZEAL PHARMA